A5008149243- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Autoimmune and Inflammatory Disorders Research
- Biosimilars and Bioanalytical Methods
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Colorectal Cancer Screening and Detection
- Celiac Disease Research and Management
- Health Systems, Economic Evaluations, Quality of Life
- Chronic Lymphocytic Leukemia Research
- Pregnancy and Medication Impact
- Colorectal Cancer Treatments and Studies
- Diagnosis and treatment of tuberculosis
- Liver Diseases and Immunity
- Adolescent and Pediatric Healthcare
- Systemic Lupus Erythematosus Research
- Gastrointestinal motility and disorders
- Pharmaceutical studies and practices
- Tuberculosis Research and Epidemiology
- Acute Lymphoblastic Leukemia research
- Gut microbiota and health
- Mycobacterium research and diagnosis
University of Calgary
2016-2025
Inserm
2024
McGill University Health Centre
2024
University of California, San Diego
2022
Soroka Medical Center
2021
The Technological College of Beer Sheva
2021
Janssen (United Kingdom)
2021
Alberta Bible College
2017-2020
Humanitas University
2020
AbbVie (Germany)
2020
In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown.
Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease the CLASSIC I trial.To evaluate long term efficacy and safety of adalimumab maintenance therapy a follow-on randomised controlled trial (CLASSIC II).In preceding trial, 299 moderate to severe naive tumour necrosis factor antagonists received induction 40 mg/20 mg, 80 mg/40 or 160 mg/80 placebo, at 0 2. In all, 276 from enrolled II open-label mg (week 4 I) 2; 55 both were re-randomised every other...
The efficacy of ustekinumab, an antagonist the p40 subunit interleukin-12 and interleukin-23, as induction maintenance therapy in patients with ulcerative colitis is unknown.We evaluated ustekinumab 8-week 44-week moderate-to-severe colitis. A total 961 were randomly assigned to receive intravenous dose (either 130 mg [320 patients] or a weight-range-based that approximated 6 per kilogram body weight [322]) placebo (319). Patients who had response 8 weeks after administration again...
Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF infliximab. No anti-TNF agent has been evaluated prospectively in had responded another and then lost that response or were intolerant of agent. Objective: To determine whether adalimumab induces remissions more frequently than placebo adult have symptoms despite infliximab therapy cannot take because adverse events. Design:...
Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue.We conducted two controlled trials to evaluate natalizumab as induction maintenance therapy in patients with active Crohn's disease. In the first trial, 905 were randomly assigned receive 300 mg of or placebo at weeks 0, 4, 8. The primary outcome was response, defined by decrease Disease Activity Index (CDAI) score least 70 points, week 10. second 339 who had...
<h3>Objective</h3> The aim of this study was to assess the efficacy and safety adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for induction clinical remission in anti-TNF naïve patients with moderately severely active ulcerative colitis. <h3>Methods</h3> This 8-week, multicentre, randomised, double-blind, placebo-controlled (NCT00385736), conducted at 94 centres North America Europe, enrolled ambulatory adult Mayo score ≥6 points endoscopic...
<h3>Objective</h3> Vedolizumab is a gut-selective antibody to α<sub>4</sub>β<sub>7</sub> integrin for the treatment of ulcerative colitis (UC) and Crohn9s disease (CD). We report an integrated summary safety vedolizumab. <h3>Design</h3> Safety data (May 2009–June 2013) from six trials vedolizumab were integrated. Adverse events evaluated in patients who received ≥1 dose or placebo reported as exposure-adjusted incidence rates number experiencing event per 100 person-years (PYs) exposure....
Fusobacterium nucleatum is a heterogeneous oral pathogen that also common resident of the human gut mucosa. Given some strains F. are known to be invasive and proinflammatory in mucosa, we compared isolated from patients with inflammatory bowel disease (IBD) healthy controls determine 1) whether this species was more commonly associated IBD patients; 2) gut-derived showed an increased capacity for invasion.Biopsy material obtained 56 adult undergoing colonoscopy colon cancer screening...